Triple-negative breast cancer represents a disproportionately higher percentage of breast cancer deaths and has a higher rate of recurrence.
CLEVELAND — A study for a vaccine aimed at preventing triple-negative breast cancer — the most aggressive and lethal form of the disease — has been opened up by researchers at the Cleveland Clinic, it was announced on Tuesday.
The phase I trial is aiming to determine the maximum dose of the vaccine that can be tolerated by patients with early-stage triple-negative breast cancer and to characterize and optimize the body's immune response. Recently, a new investigational drug application for the vaccine was approved by the U.S. Food and Drug Administration, clearing the way for the Cleveland Clinic and its partner, Anixa Biosciences Inc., to begin the study.
Triple-negative breast cancer remains the most challenging form of the disease to treat. But now, at the Cleveland Clinic, a first step is being made toward creating a vaccine to …